Frederick, MD (PRWEB) June 13, 2016
RoosterBio Inc announces the commercial launch of a new xeno-free version of their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. This xeno-free media formulation extends RoosterBio’s portfolio of bioprocess media engineered to streamline culture processes, minimize processing time, significantly decrease production costs, reduce regulatory burden and simplify the transition into scalable platforms for clinical and commercial adult stem cell manufacturing.
The newly launched High Performance Media XF system is devoid of any xeno-sourced raw materials, and maintains the economic and production efficiency of RoosterBio’s original, customer-trusted High Performance Media formulation. RoosterBio’s innovative bioprocess media products simply and consistently produce greater than 100 fold expansion of adult stem cells within 8-10 days of culture, while the critical hMSC functional parameters remain intact. The RoosterBio cell and media systems are the only systems on the market designed for a “batch” culture process, which eliminates the need for labor-intensive and costly media exchanges between passages. These adult stem cell systems are being rapidly adopted by industry participants, and are enabling a new era of efficiency and productivity in the Regenerative Medicine field.
Jon Rowley, CEO of RoosterBio stated:
“Media has always been a regulatory burden and a major cost driver in biomanufacturing processes. RoosterBio’s bioprocess media systems for adult stem cells are driving efficiencies in the field reminiscent of the exponential improvements in monoclonal antibody yields over the last 30 years. We are truly experiencing a paradigm shift in Regenerative Medicine today. The key metric for media productivity is “Millions of Cells produced per Liter of Media”. Thus, we designed a media focused on optimizing this metric and it has led to significant manufacturing gains. Our cell and media systems provide a 9 fold enhancement in million cells produced per liter of media utilized in culture expansion when compared to the market leading cell and media systems (outlined in our corporate blog), and we have now expanded our product portfolio to include regulatory friendly xeno-free formulations.”
RoosterBio continues to broaden their portfolio of product formats, providing solutions for an extensive range of Regenerative Medicine therapeutic categories. The evolving product offerings enable researchers and product developers to perform small scale screening studies, large scale development studies, and now, clinically-relevant manufacturing bioprocess implementation using the new xeno-free media product. RoosterBio also offers various adult stem cell product configurations including 1, 10, and 50 million cell vials, with highly engineered bioprocess media systems, as well as pre-assembled working cell banks and kits for rapidly achieving stem cell biomass.
About RoosterBio, Inc.:
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read the blog “Democratizing Cell Technologies” (http://www.roosterbio.blogspot.com).